ARTICLE | Clinical News

EnVivo preclinical data

July 26, 2010 7:00 AM UTC

In a transgenic mouse model of AD, daily oral EVP-0015962 significantly reduced the production of beta amyloid 42 as measured by plaque count, surface area and aggregated amyloid beta in the brain at 12 months. EVP-0015962 also reversed behavioral deficits and reduced brain inflammation associated with amyloid plaque buildup. Data were presented at the International Conference on Alzheimer's Disease in Honolulu. ...